Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: A subgroup analysis of a randomized trial (CME)

Transfusion

Volumn 54, Issue 10, 2014, Pages 2385-2393

  Stanworth, Simon J ^a,b,c   Estcourt, Lise J ^a,b,c   Llewelyn, Charlotte A ^a,b,c   Murphy, Michael F ^a,b,c   Wood, Erica M ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ADVERSE EFFECTS; AGED; AUTOTRANSPLANTATION; CLINICAL TRIAL; COMPLICATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PRIMARY PREVENTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84908095878     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12646     Document Type: Article

References (25)

1. Heddle N, Cook R, Tinmouth A, et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-1573.
2. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-1875.
3. Tinmouth A, Tannock IF, Crump M, et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004; 44: 1711-1719.
4. Sensebe L, Giraudeau B, Bardiaux L, et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005; 105: 862-864.
5. Diedrich B, Remberger M, Shanwell A, et al. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005; 45: 1064-1072.
6. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15: 1143-1149.
7. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. N Engl J Med 2013; 368: 1771-1780.
8. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380: 1309-1316.
9. Estcourt LJ, Stanworth SJ, Murphy MF,. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 2011; 154: 425-440.
10. Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24: 163-171.
11. Kahan BC, Morris TM,. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012; 345: e5840.
12. Kahan BC, Morris TP,. Improper analysis of trials randomised using stratified blocks or minimisation. Stat Med 2012; 31: 328-340.
13. British Committee for Standards in Haematology and Blood Transfusion Task Force (Chairman P. Kelsey). Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
14. Estcourt LJ, Heddle N, Kaufman R, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013; 53: 1531-1543.
15. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007; 357: 2189-2194.
16. Altman DG, Bland JM,. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.
17. Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010; 340: c117.
18. Schiffer CA,. Haematological cancer: prophylactic platelet transfusion is frequently not necessary. Nat Rev Clin Oncol 2013; 10: 431-432.
19. Morowski M, Vogtle T, Kraft P, et al. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice. Blood 2013; 121: 4938-4947.
20. Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-4964.
21. McCullough J, Vesole D, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-1541.
22. Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/μL versus 20,000/μL trigger. Biol Blood Marrow Transplant 2002; 8: 569-576.
23. Estcourt LJ,. Risk factors of intra-cranial haemorrhage in thrombocytopenic haematology patients: a case-control study. In: ISRCTN Register. 2011 ed: Clinical Trials Register; 2011:ISRCTN05026912.
24. Williamson LM, Devine DV,. Challenges in the management of the blood supply. Lancet 2013; 381: 1866-1875.
25. Wardrop D, Estcourt L, Brunskill SJ, et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev 2013;(7): CD009733.